CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Nextpharma Technologies Holding Ltd (OLD) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Nextpharma Technologies Holding Ltd (OLD)
Suite 612/613, 83 Victoria Street
Phone: +44 1483479120p:+44 1483479120 LONDON, SW1H 0HW  United Kingdom

Business Summary
BRIEF: For the fiscal year ended 31 December 2015, Nextpharma Technologies Holding Ltd revenues decreased 43% to EUR2.3M. Net income totaled EUR4.1M vs. loss of EUR7.5M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net Income reflects Income from share in group undertakings increase from EUR500K to EUR10.6M (income).

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/201512/31/2015Yes----

General Information
Outstanding Shares: 28,493,523 (As of 12/31/2015)


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023